Bangkok: The Stock Exchange of Thailand (SET) has enforced a trading suspension on shares of DOD Biotech Public Company Limited after receiving directives from the Securities and Exchange Commission (SEC) to revise its financial statements for the first quarter of 2026.

According to Thai News Agency, the SET has applied both SP and CS markers to the DOD securities. This action follows the SEC's notification to DOD to amend its Q1/2026 financial statements. The suspension commenced on June 26, 2026, and is scheduled to be lifted on June 29, 2026. The SEC's order arises from insufficient information in DOD's financial documents, particularly concerning transactions related to land purchase deposits, construction advances, and procurement of raw materials, machinery, and services.

The SEC has highlighted the lack of information on the progress of asset delivery and services associated with these transactions. Additionally, DOD's auditors were unable to verify the commercial benefits of these deals. As a result, the SEC has instructed DOD to work with auditors to review and amend the financial statements. These revised statements, along with a disclosure report, must be submitted to the SEC in accordance with Section 56 of the Securities and Exchange Act B.E. 2535 (1992). Furthermore, DOD is required to publicly disclose the amended financial statements via the SETLink system by July 27, 2026.